Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Randomized Pilot part of the trial:
- People who are planned to receive a type of targeted radiation treatment called Stereotactic Body Radiotherapy (SBRT) for a confirmed or suspected form of lung cancer known as NSCLC
- People who are older than 18 years of age
- People who are able to understand and agree to participate in the study
Safety Trial part of the trial:
- People who are planned to receive a precise, high-dose radiation treatment to all sites of NSCLC that has started growing again after a first treatment (such as immunotherapy or a targeted drug called a TKI), where fewer than 5 separate areas of the cancer are growing
- People who are older than 18 years of age
- People who are able to understand and agree to participate in the study
Who may not be able to join:
Randomized Pilot part of the trial:
- People who have taken antibiotics, antifungal, antiviral, or antiparasitic medicines in the 4 weeks before joining the study
- People who currently have an active infection with a fever above 100°F (37.8°C)
- People who have taken steroid medicines, methotrexate, or other medicines that suppress the immune system in the 4 weeks before joining the study
- People who have received chemotherapy in the 4 weeks before radiation treatment, or who would need chemotherapy during radiation or before a specific follow-up sample is collected 30 days after treatment
- People with a documented history of HIV, Hepatitis B (HBV), or Hepatitis C (HCV)
- People with active, uncontrolled gut or bowel conditions, such as inflammatory bowel disease, moderate or severe irritable bowel syndrome, ongoing gut infections, persistent diarrhea of unknown cause, a bowel infection called Clostridium difficile within 2 years of their lung cancer diagnosis, or an untreated stomach infection called Helicobacter pylori
- People who have had major surgery on their digestive system in the past 5 years (removal of the gallbladder or appendix is an exception), or who have had a significant bowel removal surgery at any point in their life
- People who take regular anti-diarrhoea medicines
- People who take probiotic supplements
Safety Trial part of the trial:
- People who have untreated cancer that has spread to the brain or the lining around the brain or spinal cord
- People who have taken antibiotics, antifungal, antiviral, or antiparasitic medicines in the 4 weeks before joining the study
- People who currently have an active infection with a fever above 100°F (37.8°C)
- People who have taken oral steroid medicines, methotrexate, or other medicines that suppress the immune system in the 4 weeks before joining the study
- People who have received chemotherapy in the 4 weeks before radiation treatment, or who would need chemotherapy during radiation or before a specific follow-up sample is collected 30 days after treatment
- People with a documented history of HIV, Hepatitis B (HBV), or Hepatitis C (HCV)
- People who take daily anti-diarrhoea medicines
- People who have used probiotic supplements in the 4 weeks before radiation treatment or during radiation treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Steven Feigenberg, MD, University of Pennsylvania
Phone: 267-250-9244
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Randomized Pilot: Th1 immune response measured by cytokine expression (IFN gamma).; Randomized Pilot: the safety of the addition of vancomycin to Stereotactic Body Radiotherapy; Safety Trial: the safety of the addition of vancomycin to precision hypofractionated radiation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.